Cargando…

A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma

Chemotherapy and immunotherapy failed to deliver decisive results in the systemic treatment of metastatic renal cell carcinoma. Agents representing the current standards operate on members of the RAS signal transduction pathway. Sunitinib (targeting vascular endothelial growth factor), temsirolimus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mihály, Z, Sztupinszki, Z, Surowiak, P, Győrffy, B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434473/ https://www.ncbi.nlm.nih.gov/pubmed/22515521 http://dx.doi.org/10.2174/156800912802429265

Ejemplares similares

PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer
por: Munkácsy, G, et al.
Publicado: (2010)

An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases
por: Semenescu, Liliana Eleonora, et al.
Publicado: (2023)

Targeted therapy for metastatic renal cell carcinoma
por: Patel, P H, et al.
Publicado: (2006)

The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma
por: Unnithan, Jaya, et al.
Publicado: (2007)

Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Review of the Historical Literature and Its Role in the Era of Targeted Molecular Therapy
por: Aslam, Muhammad Z., et al.
Publicado: (2014)

Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models
por: Sztupinszki, Zsófia, et al.
Publicado: (2016)

Metastatic renal carcinoma comprehensive prognostic system
por: Atzpodien, J, et al.
Publicado: (2003)

Targeted Therapy for Metastatic Renal Carcinoma: an Update
por: da Silva, Rodrigo Donalisio, et al.
Publicado: (2014)

The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma
por: Rathi, Nityam, et al.
Publicado: (2019)

Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
por: Győrffy, Balázs, et al.
Publicado: (2013)

Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review
por: Raman, Rachna, et al.
Publicado: (2015)

Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
por: Dizman, Nazli, et al.
Publicado: (2020)

Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy
por: Wang, Lisha, et al.
Publicado: (2014)

Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies
por: Guha, Avirup, et al.
Publicado: (2022)

Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in Korea
por: Lee, Jee Han, et al.
Publicado: (2010)

Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma
por: Chow, Ryan D, et al.
Publicado: (2023)

Systemic therapy in metastatic renal cell carcinoma
por: Bedke, Jens, et al.
Publicado: (2016)

Sequential Therapy in Metastatic Renal Cell Carcinoma
por: Hirsch, Bradford R., et al.
Publicado: (2016)

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
por: Grünwald, V, et al.
Publicado: (2011)

The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy
por: Yu, Xiaoteng, et al.
Publicado: (2015)

Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma?
por: Wong, Emily C.L., et al.
Publicado: (2019)

Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma
por: Dawsey, Scott J., et al.
Publicado: (2021)

Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview
por: Internò, Valeria, et al.
Publicado: (2021)

Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma
por: Stenehjem, David D., et al.
Publicado: (2019)

Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma
por: Nerich, Virginie, et al.
Publicado: (2014)

A Comprehensive Prognostic Stratification for Patients with Metastatic Renal Clear Cell Carcinoma
por: Cho, Kang Su, et al.
Publicado: (2008)

Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma
por: Shao, Zhiying, et al.
Publicado: (2016)

Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies
por: Procopio, G, et al.
Publicado: (2012)

Improved prognosis for elderly patients with metastatic renal cell carcinoma in the era of targeted therapy
por: Teishima, Jun, et al.
Publicado: (2021)

Molecular Targeted Therapy in the Management of Recurrent and Metastatic Nasopharyngeal Carcinoma: A Comprehensive Literature Review
por: Almobarak, Abdulaziz A, et al.
Publicado: (2019)

Axitinib in sequential therapy in metastatic renal cell carcinoma
por: Kuchar, Agata, et al.
Publicado: (2016)

Identifying Resistance Mechanisms against Five Tyrosine Kinase Inhibitors Targeting the ERBB/RAS Pathway in 45 Cancer Cell Lines
por: Pénzváltó, Zsófia, et al.
Publicado: (2013)

Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy
por: Song, Yan, et al.
Publicado: (2016)

Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy
por: Kim, Sung Han, et al.
Publicado: (2016)

Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma
por: Chrom, Pawel, et al.
Publicado: (2018)

Association of lncRNA and transcriptome intersections with response to targeted therapy in metastatic renal cell carcinoma
por: Tesarova, Tereza, et al.
Publicado: (2023)

Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?
por: Mihály, Zsuzsanna, et al.
Publicado: (2012)

The current status of immunobased therapies for metastatic renal-cell carcinoma
por: Sathianathen, Niranjan J, et al.
Publicado: (2017)

Changes in therapy and survival of metastatic renal cell carcinoma in Estonia
por: Jürgens, Hannes, et al.
Publicado: (2020)

Prognosis of metastatic renal cell carcinoma with first‐line interferon‐α therapy in the era of molecular‐targeted therapy
por: Kawano, Yoshiaki, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3sae1bpl7fpkd9iv8hojofi4m2